Institutional profile: Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai

Stuart A. Scott; Aniwaa Owusu Obeng; Mariana R. Botton; Yao Yang; Erick R. Scott; Stephen B. Ellis; Richard Wallsten; Tom Kaszemacher; Xiang Zhou; Rong Chen; Paola Nicoletti; Hetanshi Naik; Eimear E. Kenny; Aida Vega; Eva Waite; George A. Diaz; Joel Dudley; Jonathan L. Halperin; Lisa Edelmann; Andrew Kasarskis; Jean Sébastien Hulot; Inga Peter; Erwin P. Bottinger; Kurt Hirschhorn; Pamela Sklar; Judy H. Cho; Robert J. Desnick; Eric E. Schadt

doi:10.2217/pgs-2017-0137

Institutional profile: Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai

Stuart A. Scott, Aniwaa Owusu Obeng, Mariana R. Botton, Yao Yang, Erick R. Scott, Stephen B. Ellis, Richard Wallsten, Tom Kaszemacher, Xiang Zhou, Rong Chen, Paola Nicoletti, Hetanshi Naik, Eimear E. Kenny, Aida Vega, Eva Waite, George A. Diaz, Joel Dudley, Jonathan L. Halperin, Lisa Edelmann, Andrew KasarskisJean Sébastien Hulot, Inga Peter, Erwin P. Bottinger, Kurt Hirschhorn, Pamela Sklar, Judy H. Cho, Robert J. Desnick, Eric E. Schadt

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.

Original language	English
Pages (from-to)	1381-1386
Number of pages	6
Journal	Pharmacogenomics
Volume	18
Issue number	15
DOIs	https://doi.org/10.2217/pgs-2017-0137
State	Published - Oct 2017

Keywords

Icahn School of Medicine at Mount Sinai
clinical implementation
discovery
education
genetic testing
pharmacogenetics
pharmacogenomics

Access to Document

10.2217/pgs-2017-0137

Cite this

Scott, S. A., Owusu Obeng, A., Botton, M. R., Yang, Y., Scott, E. R., Ellis, S. B., Wallsten, R., Kaszemacher, T., Zhou, X., Chen, R., Nicoletti, P., Naik, H., Kenny, E. E., Vega, A., Waite, E., Diaz, G. A., Dudley, J., Halperin, J. L., Edelmann, L., ... Schadt, E. E. (2017). Institutional profile: Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. Pharmacogenomics, 18(15), 1381-1386. https://doi.org/10.2217/pgs-2017-0137

@article{68fcb14e835945e4814b5dc766cffb18,

title = "Institutional profile: Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai",

abstract = "For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.",

keywords = "Icahn School of Medicine at Mount Sinai, clinical implementation, discovery, education, genetic testing, pharmacogenetics, pharmacogenomics",

author = "Scott, {Stuart A.} and {Owusu Obeng}, Aniwaa and Botton, {Mariana R.} and Yao Yang and Scott, {Erick R.} and Ellis, {Stephen B.} and Richard Wallsten and Tom Kaszemacher and Xiang Zhou and Rong Chen and Paola Nicoletti and Hetanshi Naik and Kenny, {Eimear E.} and Aida Vega and Eva Waite and Diaz, {George A.} and Joel Dudley and Halperin, {Jonathan L.} and Lisa Edelmann and Andrew Kasarskis and Hulot, {Jean S{\'e}bastien} and Inga Peter and Bottinger, {Erwin P.} and Kurt Hirschhorn and Pamela Sklar and Cho, {Judy H.} and Desnick, {Robert J.} and Schadt, {Eric E.}",

note = "Publisher Copyright: {\textcopyright} 2017 Future Medicine Ltd.",

year = "2017",

month = oct,

doi = "10.2217/pgs-2017-0137",

language = "English",

volume = "18",

pages = "1381--1386",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "15",

}

Scott, SA, Owusu Obeng, A, Botton, MR, Yang, Y, Scott, ER, Ellis, SB, Wallsten, R, Kaszemacher, T, Zhou, X, Chen, R, Nicoletti, P, Naik, H, Kenny, EE, Vega, A, Waite, E, Diaz, GA, Dudley, J , Halperin, JL , Edelmann, L , Kasarskis, A, Hulot, JS, Peter, I , Bottinger, EP , Hirschhorn, K, Sklar, P, Cho, JH, Desnick, RJ & Schadt, EE 2017, 'Institutional profile: Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai', Pharmacogenomics, vol. 18, no. 15, pp. 1381-1386. https://doi.org/10.2217/pgs-2017-0137

TY - JOUR

T1 - Institutional profile

T2 - Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai

AU - Scott, Stuart A.

AU - Owusu Obeng, Aniwaa

AU - Botton, Mariana R.

AU - Yang, Yao

AU - Scott, Erick R.

AU - Ellis, Stephen B.

AU - Wallsten, Richard

AU - Kaszemacher, Tom

AU - Zhou, Xiang

AU - Chen, Rong

AU - Nicoletti, Paola

AU - Naik, Hetanshi

AU - Kenny, Eimear E.

AU - Vega, Aida

AU - Waite, Eva

AU - Diaz, George A.

AU - Dudley, Joel

AU - Halperin, Jonathan L.

AU - Edelmann, Lisa

AU - Kasarskis, Andrew

AU - Hulot, Jean Sébastien

AU - Peter, Inga

AU - Bottinger, Erwin P.

AU - Hirschhorn, Kurt

AU - Sklar, Pamela

AU - Cho, Judy H.

AU - Desnick, Robert J.

AU - Schadt, Eric E.

PY - 2017/10

Y1 - 2017/10

N2 - For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.

AB - For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.

KW - Icahn School of Medicine at Mount Sinai

KW - clinical implementation

KW - discovery

KW - education

KW - genetic testing

KW - pharmacogenetics

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=85032448160&partnerID=8YFLogxK

U2 - 10.2217/pgs-2017-0137

DO - 10.2217/pgs-2017-0137

M3 - Article

C2 - 28982267

AN - SCOPUS:85032448160

SN - 1462-2416

VL - 18

SP - 1381

EP - 1386

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 15

ER -

Institutional profile: Translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai

Abstract

Keywords

Access to Document

Fingerprint

Cite this